Drug name - Xelstrym

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US8591941 NOVEN PHARMS INC Transdermal drug delivery device including an occlusive backing
Oct, 2025

(2 years from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US9456993 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(10 years from now)

US9474722 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
4.5MG/9HR SYSTEM;TRANSDERMAL Discontinued
9MG/9HR SYSTEM;TRANSDERMAL Discontinued
13.5MG/9HR SYSTEM;TRANSDERMAL Discontinued
18MG/9HR SYSTEM;TRANSDERMAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in